Shares of TG Therapeutics Inc (NASDAQ:TGTX) traded down 1% on Tuesday . The stock traded as low as $4.08 and last traded at $4.05. 48,260 shares changed hands during mid-day trading, a decline of 96% from the average session volume of 1,205,946 shares. The stock had previously closed at $4.09.
Several analysts recently weighed in on the company. BidaskClub raised TG Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price objective on shares of TG Therapeutics in a research note on Friday, November 2nd. Zacks Investment Research raised TG Therapeutics from a “hold” rating to a “buy” rating and set a $5.75 price objective on the stock in a research note on Friday, November 16th. ValuEngine raised TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, October 24th. Finally, B. Riley assumed coverage on TG Therapeutics in a research note on Tuesday, January 8th. They issued a “buy” rating and a $10.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. TG Therapeutics has a consensus rating of “Buy” and a consensus price target of $14.95.
The company has a market cap of $339.06 million, a P/E ratio of -2.12 and a beta of 1.84.
TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Friday, November 9th. The biopharmaceutical company reported ($0.43) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.12. TG Therapeutics had a negative return on equity of 185.20% and a negative net margin of 99,001.33%. The firm had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million. As a group, equities analysts expect that TG Therapeutics Inc will post -2.03 EPS for the current fiscal year.
In other news, CFO Sean A. Power sold 37,275 shares of TG Therapeutics stock in a transaction dated Wednesday, January 2nd. The stock was sold at an average price of $4.13, for a total transaction of $153,945.75. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 15.10% of the company’s stock.
Several institutional investors have recently bought and sold shares of the stock. Teachers Advisors LLC lifted its stake in shares of TG Therapeutics by 4.3% in the third quarter. Teachers Advisors LLC now owns 127,405 shares of the biopharmaceutical company’s stock worth $713,000 after acquiring an additional 5,221 shares during the period. MetLife Investment Advisors LLC lifted its stake in shares of TG Therapeutics by 35.2% in the second quarter. MetLife Investment Advisors LLC now owns 28,284 shares of the biopharmaceutical company’s stock worth $372,000 after acquiring an additional 7,358 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of TG Therapeutics by 3.8% in the third quarter. Bank of New York Mellon Corp now owns 286,843 shares of the biopharmaceutical company’s stock worth $1,606,000 after acquiring an additional 10,518 shares during the period. Forbes J M & Co. LLP acquired a new position in shares of TG Therapeutics in the fourth quarter worth approximately $44,000. Finally, Swiss National Bank increased its holdings in TG Therapeutics by 13.2% in the third quarter. Swiss National Bank now owns 108,900 shares of the biopharmaceutical company’s stock worth $610,000 after purchasing an additional 12,700 shares in the last quarter. 57.38% of the stock is currently owned by institutional investors.
WARNING: This piece of content was reported by Highlight Press and is owned by of Highlight Press. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://highlightpress.com/2019/01/29/tg-therapeutics-tgtx-stock-price-down-1.html.
TG Therapeutics Company Profile (NASDAQ:TGTX)
TG Therapeutics, Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.
Recommended Story: Price to Earnings Ratio (PE) Basics
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.